 |
|
A Randomized Controlled Trial of Varying Radiation Doses in the Treatment of Choroidal Melanoma
Evangelos S. Gragoudas, MD;
Anne Marie Lane, MPH;
Susan Regan, PhD;
Wenjun Li, MS;
Heidi E. Judge, BA;
John E. Munzenrider, MD;
Johanna M. Seddon, MD;
Kathleen M. Egan, ScD
Arch Ophthalmol. 2000;118:773-778.
Objective To determine if a reduction in proton radiation dose from the standard dose of 70 cobalt gray equivalents (CGE) to 50 CGE would decrease radiation-induced complications, thereby improving visual prognosis, without compromising local tumor control for patients with uveal melanoma at high risk of these complications.
Design Randomized, double-masked clinical trial.
Participants A total of 188 patients with small or medium-sized choroidal melanomas (<15 mm in diameter and <5 mm in height) near the optic disc or macula (within 4 disc diameters of either structure).
Methods Patients were treated with proton beam therapy at doses of either 50 CGE or 70 CGE between October 1989 and July 1994, and followed up biannually through April 1998. Outcomes included visual acuity, radiation complications, melanoma recurrence, and metastasis.
Results Proportions of patients retaining visual acuity of at least 20/200 were similar in the 2 dose groups at 5 years after radiation (approximately 55%). Similar numbers of patients in each group experienced tumor regrowth (2 patients at 50 CGE vs 3 patients at 70 CGE; P>.99) and metastasis (7 patients at 50 CGE vs 8 patients at 70 CGE;P=.79). Five-year rates of radiation maculopathy also were similar (for both groups, approximately 75% for tumors within 1 disc diameter and 40% for tumors >1 disc diameter from the macula). Rates of radiation papillopathy were nonsignificantly decreased in the 50-CGE treatment group when tumors were located 1 disc diameter or less from the optic disc (P=.20). Patients treated with the lower dose also experienced significantly less visual field loss.
Conclusions This level of dose reduction did not result in a lesser degree of visual acuity loss. The lower-dose group did experience significantly less visual field loss. Local tumor recurrence and metastatic death rates were similar in both dose groups.
From the Retina Service, Massachusetts Eye and Ear Infirmary, Boston (Drs Gragoudas, Regan, Seddon, and Egan, Mss Lane and Judge, and Mr Li); the Department of Epidemiology, Harvard School of Public Health, Boston (Drs Seddon and Egan); and the Department of Radiation Oncology, Massachusetts General Hospital, Boston (Dr Munzenrider).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2000;118(6):867.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Systematic Review: Charged-Particle Radiation Therapy for Cancer
Terasawa et al.
ANN INTERN MED 2009;151:556-565.
ABSTRACT
| FULL TEXT
Particle Radiation Therapy Using Proton and Heavier Ion Beams
Schulz-Ertner and Tsujii
JCO 2007;25:953-964.
ABSTRACT
| FULL TEXT
Manganese-Enhanced MRI of Human Choroidal Melanoma Xenografts
Braun et al.
IOVS 2007;48:963-967.
ABSTRACT
| FULL TEXT
Proton Beam Irradiation of Uveal Melanomas: The First 30 Years The Weisenfeld Lecture
Gragoudas
IOVS 2006;47:4666-4673.
FULL TEXT
Patient neutron dose equivalent exposures outside of the proton therapy treatment field
Polf et al.
Radiat Prot Dosimetry 2005;115:154-158.
ABSTRACT
| FULL TEXT
Evidence-Based Estimates of Outcome in Patients Irradiated for Intraocular Melanoma
Gragoudas et al.
Arch Ophthalmol 2002;120:1665-1671.
ABSTRACT
| FULL TEXT
|
